uniQure N.V Cash Flow Conversion Efficiency
uniQure N.V cash flow conversion efficiency. Based on the latest financial reports, uniQure N.V (UQ1) has a cash flow conversion efficiency ratio of -0.256x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.24 Million ≈ $-44.71 Million USD) by net assets (€149.34 Million ≈ $174.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of uniQure N.V (2016–2025)
Cash flow conversion efficiency of uniQure N.V from 2016 to 2025. This chart illustrates how uniQure N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. View uniQure N.V stock price for real-time trading data and today's change.
uniQure N.V Cash Flow Conversion Ratio Explained
uniQure N.V cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
uniQure N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of uniQure N.V ranked by their cash flow conversion efficiency. Also see how much is uniQure N.V worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
0.028x |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
N/A |
|
ShenZhen QiangRui Precision Technology Co. Ltd.
SHE:301128
|
0.008x |
|
Sk Gas
KO:018670
|
0.070x |
|
Zhe Jiang Dali Technology Co Ltd
SHE:002214
|
0.030x |
|
Insperity Inc
NYSE:NSP
|
-1.000x |
|
Flowers Foods Inc
NYSE:FLO
|
0.083x |
|
Orange Belgium SA
BR:OBEL
|
0.124x |
Annual Cash Flow Conversion Efficiency for uniQure N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of uniQure N.V from 2016 to 2025. Review how much free cash does uniQure N.V generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €198.90 Million ≈ $232.54 Million |
€-177.96 Million ≈ $-208.06 Million |
-0.895x | -103.31% |
| 2024-12-31 | €-6.75 Million ≈ $-7.89 Million |
€-182.73 Million ≈ $-213.63 Million |
27.063x | +3951.28% |
| 2023-12-31 | €207.67 Million ≈ $242.79 Million |
€-145.93 Million ≈ $-170.61 Million |
-0.703x | -130.59% |
| 2022-12-31 | €476.01 Million ≈ $556.50 Million |
€-145.06 Million ≈ $-169.59 Million |
-0.305x | -163.05% |
| 2021-12-31 | €595.78 Million ≈ $696.52 Million |
€287.96 Million ≈ $336.65 Million |
0.483x | +187.44% |
| 2020-12-31 | €243.91 Million ≈ $285.15 Million |
€-134.83 Million ≈ $-157.63 Million |
-0.553x | -80.96% |
| 2019-12-31 | €323.06 Million ≈ $377.69 Million |
€-98.68 Million ≈ $-115.37 Million |
-0.305x | +27.85% |
| 2018-12-31 | €179.61 Million ≈ $209.98 Million |
€-76.04 Million ≈ $-88.90 Million |
-0.423x | +41.14% |
| 2017-12-31 | €89.36 Million ≈ $104.47 Million |
€-64.27 Million ≈ $-75.14 Million |
-0.719x | +36.60% |
| 2016-12-31 | €63.63 Million ≈ $74.39 Million |
€-72.19 Million ≈ $-84.40 Million |
-1.134x | -- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more